*Please scroll down to the bottom of the page for the final deliverable.
Crescendo Biologics develops highly differentiated products for cancer therapy using the proprietary Humabody® platform. Humabodies are small, robust protein therapeutics that have fully human VH domains. The origin and size of these Humabodies present distinct advantages over conventional therapeutic antibodies. Crescendo is currently focused on two development programs. These are immuno-oncology modulators and Humabody®-drug conjugates (HDCs).
The objective of this project is to attract the interest of investors, potential partners and potential collaborators. Specifically, video 1 will give an overview of the Humabody® platform.
The target audience will have a scientific background and most likely will be working in the Pharmaceutical industry.
Conventional bispecific antibodies are a powerful treatment option but are challenging to develop using existing technologies.
They are cumbersome to engineer, have bioavailability issues and may simply be too large for key applications.
In contrast, Crescendo’s fully human Humabodies are smaller, more robust, and more easily engineered.
Comprised of the smallest natural antigen-recognition portion of the IgG heavy chain,
Humabody ‘building blocks’ have superior druggability, tunable bioavailability, and can be rapidly assembled into optimally configured therapeutics.
Because Humabodies can be combined into an almost limitless number of multispecific formats,
they can engage therapeutic targets in ways that are fundamentally different from conventional antibodies, unlocking novel biology and expanding how we approach anti-cancer therapeutic development.
Crescendo is creating the next-generation of cancer therapeutics.
To learn more about how we’re developing Humabodies for oncology indications—email email@example.com